Comparable Efficacy, Disruptive Price for an Alternative EGFR TKI?

Lung Cancer Risk Prediction Model Demonstrates Readiness for Clinical Application

Using Comparative Effectiveness Data Based on Non-Randomized Study Designs to Support Regulatory, Reimbursement Decision-Making

In Measuring Outcomes, a Longer-Term View May be Needed

In Brief for June 8, 2022

Structure-Based Classification System for EGFR Mutations May Help Clinicians Personalize Treatments for More Patients

Beloved Oncologist Dr. Philip D. Bonomi to Retire June 30, 2022

Reflections on Nearly 50 Years in Oncology

More Robust Tools Needed to Predict who will Respond to Immune Checkpoint Inhibitors

In Brief for June 22, 2022